Jazz Pharmaceuticals Plc Forecast, price target & analysts
Jazz Pharmaceuticals Plc Target price 2025 - Analyst rating & recommendation
Jazz Pharmaceuticals Plc Classifications & Recommendation:
Jazz Pharmaceuticals Plc Price Target
| Target Price | $187.67 |
| Price | $143.27 |
| Potential |
30.99%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Jazz Pharmaceuticals Plc 2026 .
The average Jazz Pharmaceuticals Plc target price is $187.67.
This is
30.99%
register free of charge
$230.00
60.54%
register free of charge
$145.00
1.21%
register free of charge
|
|
| A rating was issued by 19 analysts: 16 Analysts recommend Jazz Pharmaceuticals Plc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Jazz Pharmaceuticals Plc stock has an average upside potential 2026 of
30.99%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 4.07 | 4.30 |
| 6.12% | 5.66% | |
| EBITDA Margin | 34.08% | 45.95% |
| 0.67% | 34.83% | |
| Net Margin | 12.89% | 14.58% |
| 33.62% | 13.12% |
18 Analysts have issued a sales forecast Jazz Pharmaceuticals Plc 2025 . The average Jazz Pharmaceuticals Plc sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Jazz Pharmaceuticals Plc EBITDA forecast 2025. The average Jazz Pharmaceuticals Plc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Jazz Pharmaceuticals Plc Analysts have issued a net profit forecast 2025. The average Jazz Pharmaceuticals Plc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 8.65 | 10.34 |
| 41.80% | 19.54% | |
| P/E | 13.85 | |
| EV/Sales | 2.75 |
8 Analysts have issued a Jazz Pharmaceuticals Plc forecast for earnings per share. The average Jazz Pharmaceuticals Plc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Jazz Pharmaceuticals Plc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Jazz Pharmaceuticals Plc...
Current Jazz Pharmaceuticals Plc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays | Locked ➜ Locked | Locked | Feb 27 2025 |
| Piper Sandler | Locked ➜ Locked | Locked | Feb 26 2025 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Feb 26 2025 |
| RBC Capital | Locked ➜ Locked | Locked | Feb 26 2025 |
| Needham | Locked ➜ Locked | Locked | Feb 26 2025 |
| JP Morgan | Locked ➜ Locked | Locked | Feb 26 2025 |
| Wells Fargo | Locked ➜ Locked | Locked | Feb 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
Piper Sandler: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
JP Morgan: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
Wells Fargo: Locked ➜ Locked
|
Feb 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
